It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Chronic kidney disease (CKD) is a public health problem driven by myofibroblast accumulation, leading to interstitial fibrosis. Heterogeneity is a recently recognized characteristic in kidney fibroblasts in CKD, but the role of different populations is still unclear. Here, we characterize a proinflammatory fibroblast population (named CXCL-iFibro), which corresponds to an early state of myofibroblast differentiation in CKD. We demonstrate that CXCL-iFibro co-localize with macrophages in the kidney and participate in their attraction, accumulation, and switch into FOLR2+ macrophages from early CKD stages on. In vitro, macrophages promote the switch of CXCL-iFibro into ECM-secreting myofibroblasts through a WNT/β-catenin-dependent pathway, thereby suggesting a reciprocal crosstalk between these populations of fibroblasts and macrophages. Finally, the detection of CXCL-iFibro at early stages of CKD is predictive of poor patient prognosis, which shows that the CXCL-iFibro population is an early player in CKD progression and demonstrates the clinical relevance of our findings.
Fibroblast heterogeneity is a recognized feature in chronic kidney disease, and although fibrosis is integrant to the pathology, it is lesser known which of the fibroblast populations contribute. Here authors describe a population of proinflammatory fibroblasts, which are found in close proximity to macrophages and may facilitate their recruitment and acquisition of a FOLR2+, pathogenic phenotype.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 PSL Research University, Institut Curie, Stress and Cancer Laboratory, Equipe labélisée par la Ligue Nationale contre le Cancer, Paris, France (GRID:grid.440907.e) (ISNI:0000 0004 1784 3645); Inserm, U830, Paris, France (GRID:grid.7429.8) (ISNI:0000 0001 2186 6389)
2 Institut Curie Hospital Group, Department of Diagnostic and Theragnostic Medicine, Paris, France (GRID:grid.418596.7) (ISNI:0000 0004 0639 6384)
3 Paris Cité University, Inserm U1151, Department of Nephrology and Kidney Transplantation, Necker Hospital, AP-HP, Paris, France (GRID:grid.508487.6) (ISNI:0000 0004 7885 7602)
4 Paris Cité University, Department of Pathology, Necker Hospital, AP-HP, Paris, France (GRID:grid.508487.6) (ISNI:0000 0004 7885 7602)
5 Paris Cité University, Inserm, U1148, Department of Pathology, AP-HP, Bichat-Claude Bernard Hospital, Paris, France (GRID:grid.7429.8) (ISNI:0000000121866389)
6 Paris Cité University, Department of Urology, Européen George Pompidou Hospital, APHP, Paris, France (GRID:grid.50550.35) (ISNI:0000 0001 2175 4109)
7 University of Michigan, Department of Internal Medicine, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000 0004 1936 7347)
8 University of Michigan, Department of Internal Medicine, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000 0004 1936 7347); University of Michigan, Department of Computational Medicine and Bioinformatics, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000 0004 1936 7347)